Lantheus Holdings stock has logged a very large 287.3% total return over the past five years, and at around US$104.61 per share the broader valuation checks now suggest it no longer looks obviously cheap but not stretched either. With the market multiples reading as about right and a strong value score, the question is whether that past share price strength still leaves enough valuation support for new money.

• The very large 287.3% return over five years puts Lantheus Holdings among the stronger performers in its space, which naturally raises the bar for what counts as good value today.
• Expectations around the company’s ability to keep growing its imaging and diagnostics franchise can support current pricing, but any pressure on margins or slower than expected cash generation may weigh on what investors are willing to pay.
• Lantheus Holdings screens as undervalued on most of Simply Wall St’s checks, with 5 out of 6 valuation tests suggesting the shares lean cheap relative to their fundamentals.

The issue now is whether Lantheus Holdings’ current share price around US$104.61 still offers an appealing margin of safety after such a strong multi year run.

Where Does Lantheus Holdings Sit on Earnings?

The P/E ratio suits Lantheus Holdings because earnings are a core driver for how investors judge established healthcare businesses. On this measure, Lantheus Holdings trades at about 24.4x earnings, which is slightly below the Medical Equipment industry average of roughly 26.5x and well under the peer group average of about 50.8x.

A tailored fair P/E multiple for Lantheus Holdings, which reflects its sector, profitability profile and risk, sits at around 26.5x. That is close to the current 24.4x level and suggests only a modest discount to what this framework would imply, rather than a clear bargain or premium. For investors, the key question is whether the company’s earnings can justify staying around or above that fair multiple over time, because the current P/E already aligns quite closely with what the model views as reasonable.

Taken together, the P/E comparison suggests Lantheus Holdings stock is trading at roughly fair value on earnings.

The Lantheus Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Lantheus Holdings pick up where the valuation checks stop by spelling out what paths for revenue, margins and earnings would need to play out for Lantheus Holdings' stock to be worth meaningfully more or less than it is today. Instead of a single output from a ratio or model, Narratives set out the underlying future it relies on so you can watch how the real business lines up with that picture over time.

Community views on Lantheus Holdings sit on very different tracks, with one side seeing clear upside potential and the other arguing the current setup already bakes in a lot of good news.

Bull case: 19% undervalued

"Ongoing investments in AI-enabled molecular imaging, precision diagnostics, and digital workflow partnerships give Lantheus a first-mover advantage as healthcare shifts to value-based care..."

Bear case: roughly fairly valued

"Continued over-reliance on PYLARIFY as the primary revenue driver, combined with signs of market share loss and the likelihood of flat or negative PYLARIFY growth in 2026, creates vulnerability to further competitive disruption or reimbursement changes..."

Do you think there's more to the story for Lantheus Holdings? Head over to our Community to see what others are saying!

The Bottom Line

For Lantheus Holdings, the current market multiples suggest a stock that appears fairly valued rather than clearly undervalued or overvalued. The broader valuation checks lean supportive, but they no longer indicate a clear bargain. As a result, any potential upside depends more on how earnings and cash generation develop from here than on a valuation rerating.

The key question for investors is whether Lantheus Holdings can maintain growth and profitability at levels that keep its P/E near or above sector norms without relying too heavily on a single product. How that assumption plays out will likely determine whether today’s pricing represents an attractive entry point or largely reflects expectations already incorporated into the share price.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.